Nanometer magnetic particle chemiluminescence detection kit for triiodothyronine as well as preparation method and detecting method of same
A technology of triiodothyroid and nano-magnetic particles, which is applied in the biological field, can solve the problems of high preparation cost and use cost, limit the precision of the detection method, and limit the detection effect, and achieve cost advantages, good accuracy, and improve the detection effect. Effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0044] Embodiment 1 The preparation of the first reagent
[0045] (1) Materials and instruments: triiodothyronine (T3) monoclonal antibody (purity over 95wt%, concentration 2mg / mL) preserved in phosphate buffer; fluorescein isothiocyanate (FITC), carbonic acid Reagents such as sodium should be chemically pure; G-25 gel purification column was purchased from GE.
[0046] (2) Preparation steps:
[0047] ① Prepare 0.5 mg / mL FITC solution with 0.1-0.2 mol / L carbonate buffer solution with pH 9.0-10.0;
[0048] ② Add the FITC solution prepared in step ① to the antibody solution according to the ratio of triiodothyronine monoclonal antibody to FITC molecular ratio of 1:20, mix well, and let stand at room temperature for 12 hours to generate T3 antibody-FITC conjugate ;
[0049] ③Separate the reaction liquid after step ② through G-25 gel column, remove unreacted FITC, and obtain a solution containing T3 antibody-FITC conjugate (ie, FITC-labeled T3 antibody);
[0050] ④ Dilute the ...
Embodiment 2
[0051] Embodiment 2 Preparation of the second reagent
[0052] (1) Materials and instruments: T3 antigen (solid powder, purity over 95wt%); alkaline phosphatase preserved in phosphate buffer (ALP solution, ALP purity is about 99%, specific activity is about 1500U / mg, concentration is 10 mg / mL); the cross-linking agent DSS was purchased from THERMO Company, and chemical reagents such as TRIS should be chemically pure; the G-25 gel purification column was a product of GE Company.
[0053] (2) Preparation steps:
[0054] ① Take 1 mg of T3 antigen, add DMSO to dissolve the antigen to a concentration of 20-50 mg / mL, add DSS 0.5 mg, react at room temperature for 2 hours, dilute the reaction solution 1:10 with DMSO, and store it at 2-8 °C for later use;
[0055] ②Take 1mg of ALP solution, with 0.1M NaHCO pH9.5 3 Buffer Dilute the ALP solution to 1mg / ml, add the T3-DMSO solution prepared in step ① to the diluted ALP buffer for the ligation reaction, add the T3-DMSO solution to 1 / 20 ...
Embodiment 3
[0057] The preparation of embodiment 3 magnetic separation reagents
[0058] (1) Materials and instruments:
[0059] Suspension of magnetic particles: the content of magnetic particles is 5wt%, and the magnetic particles contain carboxyl (COOH) active groups. The carboxyl group content per gram (g) of magnetic particles (dry weight) is not less than 0.4 millimoles (mmol), with superparamagnetism, The diameter is between 0.5-2μm.
[0060] Anti-FITC antibody: It can be a polyclonal antibody or a monoclonal antibody, with a purity of more than 90% by weight and a dilution titer of more than 1:1 million;
[0061] 2-Morpholinoethanesulfonic acid (MES), carbodiimide (EDC), TRI S, and other reagents should be of chemical purity.
[0062] (2) Preparation steps:
[0063] ①Take 100mg of magnetic particle suspension, magnetically separate to remove the supernatant, and resuspend in 10mL of 0.05mol / L, pH4.5~5 MES buffer;
[0064] ②Add 2~4mg of anti-FITC antibody and suspend at room te...
PUM
Property | Measurement | Unit |
---|---|---|
diameter | aaaaa | aaaaa |
Sensitivity | aaaaa | aaaaa |
Sensitivity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap